JP2013501805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501805A5 JP2013501805A5 JP2012524851A JP2012524851A JP2013501805A5 JP 2013501805 A5 JP2013501805 A5 JP 2013501805A5 JP 2012524851 A JP2012524851 A JP 2012524851A JP 2012524851 A JP2012524851 A JP 2012524851A JP 2013501805 A5 JP2013501805 A5 JP 2013501805A5
- Authority
- JP
- Japan
- Prior art keywords
- test
- disorder
- neurocognitive
- neuropsychiatric
- memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 208000035475 disorder Diseases 0.000 claims 22
- 238000012360 testing method Methods 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 13
- 230000015654 memory Effects 0.000 claims 8
- 208000016192 Demyelinating disease Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000003557 neuropsychological effect Effects 0.000 claims 4
- 229960002715 nicotine Drugs 0.000 claims 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 3
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical group NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 229960004979 fampridine Drugs 0.000 claims 3
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 2
- 241001539473 Euphoria Species 0.000 claims 2
- 206010015535 Euphoric mood Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 238000012093 association test Methods 0.000 claims 2
- 230000003925 brain function Effects 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 230000010365 information processing Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 238000012030 stroop test Methods 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 230000003936 working memory Effects 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 1
- 150000003927 aminopyridines Chemical class 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23307709P | 2009-08-11 | 2009-08-11 | |
| US23306909P | 2009-08-11 | 2009-08-11 | |
| US61/233,069 | 2009-08-11 | ||
| US61/233,077 | 2009-08-11 | ||
| US23987709P | 2009-09-04 | 2009-09-04 | |
| US61/239,877 | 2009-09-04 | ||
| PCT/US2010/045211 WO2011019845A1 (en) | 2009-08-11 | 2010-08-11 | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015247850A Division JP2016074728A (ja) | 2009-08-11 | 2015-12-18 | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013501805A JP2013501805A (ja) | 2013-01-17 |
| JP2013501805A5 true JP2013501805A5 (enExample) | 2013-09-19 |
| JP6137833B2 JP6137833B2 (ja) | 2017-05-31 |
Family
ID=43586462
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524851A Expired - Fee Related JP6137833B2 (ja) | 2009-08-11 | 2010-08-11 | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 |
| JP2015247850A Pending JP2016074728A (ja) | 2009-08-11 | 2015-12-18 | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015247850A Pending JP2016074728A (ja) | 2009-08-11 | 2015-12-18 | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (8) | US20130053420A1 (enExample) |
| EP (1) | EP2464229B1 (enExample) |
| JP (2) | JP6137833B2 (enExample) |
| KR (2) | KR20120050473A (enExample) |
| CN (1) | CN102143687B (enExample) |
| AR (1) | AR077858A1 (enExample) |
| AU (1) | AU2010282509B2 (enExample) |
| BR (1) | BRPI1003991A2 (enExample) |
| CA (1) | CA2770698C (enExample) |
| ES (1) | ES2563751T3 (enExample) |
| JO (1) | JO3348B1 (enExample) |
| MX (1) | MX2012001814A (enExample) |
| RU (1) | RU2563821C2 (enExample) |
| TW (2) | TW201613585A (enExample) |
| UY (1) | UY32837A (enExample) |
| WO (1) | WO2011019845A1 (enExample) |
| ZA (1) | ZA201201001B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| US20130184316A1 (en) * | 2010-07-15 | 2013-07-18 | Andrew Hornstein | Methods for diagnosing and treating concussive disorders |
| BR112013019265A2 (pt) * | 2011-01-28 | 2016-10-11 | Acorda Therapeutics Inc | uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral |
| US10793893B2 (en) | 2011-06-30 | 2020-10-06 | Serb Sa | Methods of administering 3,4-diaminopyridine |
| WO2014138298A1 (en) | 2013-03-05 | 2014-09-12 | University Of Chicago | Treatment of demyelinating disorders |
| CA2909527A1 (en) * | 2013-04-15 | 2014-10-23 | Acorda Therapeutics, Inc. | Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines |
| DE102014221687B4 (de) * | 2014-10-24 | 2019-07-04 | Danfoss Silicon Power Gmbh | Leistungshalbleitermodul mit kurzschluss-ausfallmodus |
| DE102017115701B4 (de) * | 2017-07-12 | 2022-03-03 | Lts Lohmann Therapie-Systeme Ag | Fampridin-TTS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| WO2002072025A2 (en) * | 2001-03-14 | 2002-09-19 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Improving postsynaptic response by a combination of 4-minopyridine and agonist |
| US8007826B2 (en) * | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
-
2010
- 2010-08-10 JO JOP/2010/0284A patent/JO3348B1/ar active
- 2010-08-11 WO PCT/US2010/045211 patent/WO2011019845A1/en not_active Ceased
- 2010-08-11 MX MX2012001814A patent/MX2012001814A/es active IP Right Grant
- 2010-08-11 US US13/390,076 patent/US20130053420A1/en not_active Abandoned
- 2010-08-11 AR ARP100102953A patent/AR077858A1/es not_active Application Discontinuation
- 2010-08-11 ES ES10808713.1T patent/ES2563751T3/es active Active
- 2010-08-11 KR KR1020127006244A patent/KR20120050473A/ko not_active Ceased
- 2010-08-11 EP EP10808713.1A patent/EP2464229B1/en not_active Not-in-force
- 2010-08-11 JP JP2012524851A patent/JP6137833B2/ja not_active Expired - Fee Related
- 2010-08-11 TW TW104125993A patent/TW201613585A/zh unknown
- 2010-08-11 KR KR1020177032919A patent/KR20170128633A/ko not_active Ceased
- 2010-08-11 UY UY0001032837A patent/UY32837A/es not_active Application Discontinuation
- 2010-08-11 CA CA2770698A patent/CA2770698C/en active Active
- 2010-08-11 TW TW099126795A patent/TWI549678B/zh not_active IP Right Cessation
- 2010-08-11 CN CN201080002517.4A patent/CN102143687B/zh not_active Expired - Fee Related
- 2010-08-11 AU AU2010282509A patent/AU2010282509B2/en not_active Ceased
- 2010-08-11 BR BRPI1003991A patent/BRPI1003991A2/pt not_active Application Discontinuation
- 2010-08-11 RU RU2012108656/15A patent/RU2563821C2/ru active
-
2012
- 2012-02-10 ZA ZA2012/01001A patent/ZA201201001B/en unknown
-
2015
- 2015-12-18 JP JP2015247850A patent/JP2016074728A/ja active Pending
-
2016
- 2016-04-01 US US15/088,252 patent/US20160213661A1/en not_active Abandoned
- 2016-11-11 US US15/349,644 patent/US20170056385A1/en not_active Abandoned
-
2017
- 2017-06-20 US US15/627,871 patent/US20170281608A1/en not_active Abandoned
-
2018
- 2018-01-25 US US15/879,603 patent/US20180147193A1/en not_active Abandoned
- 2018-09-17 US US16/133,104 patent/US20190015399A1/en not_active Abandoned
-
2019
- 2019-04-26 US US16/395,495 patent/US20190247379A1/en not_active Abandoned
- 2019-12-06 US US16/705,711 patent/US20200113882A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501805A5 (enExample) | ||
| US20250345291A1 (en) | Method of treating post-traumatic stress disorder | |
| CN111201014A (zh) | 治疗过度嗜睡的方法和组合物 | |
| JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| CA3083341C (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| JP2017510607A5 (enExample) | ||
| US20190105315A1 (en) | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases | |
| Krasniqi et al. | Analgesics use in dentistry | |
| US10292977B2 (en) | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases | |
| ZA200504908B (en) | Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines | |
| US11369603B2 (en) | Use of a H3R inverse agonist for the treatment of shift work disorder | |
| KR20230154217A (ko) | 인지 장애 치료를 위한 루바다시스타트의 용도 | |
| JP6738797B2 (ja) | レット症候群治療薬 | |
| CN105287554B (zh) | 复方抗感冒药组合物及其用途 | |
| Ives et al. | Crew State and Risk Model (CSRM)-Medication Impacts on Physiologic Models for Exploration Class EVA Predictive Modeling and Operations | |
| JPWO2005027968A1 (ja) | ダウン症候群治療剤 | |
| JP2025069218A (ja) | 神経変性疾患における転倒および転倒頻度に関連する処置のための組成物および方法 | |
| Bondarieva et al. | Market research R06A antihistamines for systemic use in Ukraine | |
| Markopoulou et al. | P. 3. c. 045 Neuroleptic malignant syndrome after addition of ziprasidone to long-term treatment with risperidone | |
| NAPOLI | ACP Report: Support Family Caregivers | |
| CN104814960A (zh) | 复方抗感冒药组合物及其用途 | |
| WO1996012481A1 (en) | Autism remedy | |
| UA77796U (uk) | Композиція для лікування алергічних станів | |
| TH81176B (th) | วิธีการรักษาและป้องกัน |